Purification Of Antibodies With Nuvia aPrime 4A Hydrophobic Anion Exchange Resin

By Xuemei He, Louisa Vang, Mark Syder, Payal Khandelwal, and Daniel Yoshikawa

The global antibody therapeutics market is estimated to expand to about US$200 billion between 2023 and 2026 (Coherent Market Insights 2019, Zion Market Research 2018). This massive growth is fueled by cutting-edge research into various therapeutic aspects of antibodies in drug development. With increasing upstream cell culture titers, additional burdens are placed on making downstream antibody purification and recovery cost- and time-effective. This, in turn, results in an ever-increasing demand for innovative and advanced chromatography resins.

Downstream process development continues to evolve to support next-generation antibody therapeutics. Our new hydrophobic anion exchange mixed-mode resin, Nuvia aPrime 4A, has been developed to overcome existing challenges in antibody purification. Described here are two case studies on the purification of an acidic and a basic antibody with Nuvia aPrime 4A through bind-elute and flow-through modes of purification, respectively. The results demonstrate the ability of Nuvia aPrime 4A resin to improve process productivity and economy.